Carisma Therapeutics Inc (Carisma Therapeutics), formerly Sesen Bio Inc, is a late-stage clinical company that develops targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The company’s TFPTs genetically combines targeting antibody fragments with cytotoxic protein payloads. Carisma Therapeutics' product pipeline includes Vicinium (VB4-845) also known as oportuzumab monatox, which is used for the treatment of high-grade non-muscle invasive bladder cancer(NMIBC). The company operates in the US, the UK, and Canada. Carisma Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
245 1st St Ste 1800, Cambridge, Massachusetts, 02142-1292
Website
sesenbio.com
Telephone
1 617 4448550
No of Employees
17
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CARM (NASD)
Revenue (2021)
$40.0M
50.7%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-5817.9%
(2021 vs 2020)
Market Cap*
$67.7M
Net Profit Margin (2021)
XYZ
-3,814.2%
(2021 vs 2020)
* As of and is in US$
Carisma Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Vicineum (VB4-845): |
| Head and Neck Cancer |
| Bladder Cancer |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In March, the company merged with Carisma Therapeutics Inc. |
| 2021 | Contracts/Agreements | In August, the company entered into a licensing agreement for the registration and commercialization of Vicineum to treat patient with BCG-unresponsive non-muscle invasive bladder cancer. |
| 2020 | Contracts/Agreements | In July, the company announced a license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum in China. |
Competitor Comparison
| Key Parameters | Carisma Therapeutics Inc | Merck & Co Inc | Bristol-Myers Squibb Co | Eli Lilly and Co | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Cambridge | Kenilworth | Princeton | Indianapolis | Thousand Oaks |
| State/Province | Massachusetts | New Jersey | New Jersey | Indiana | California |
| No. of Employees | 17 | 72,000 | 34,100 | 43,000 | 26,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jay Duker | Chairman | Executive Board | 2020 | 64 |
| Thomas Cannell | Director; President; Chief Executive Officer | Executive Board | 2018 | 61 |
| Monica Forbes | Treasurer; Chief Financial Officer | Senior Management | 2019 | 48 |
| Glen MacDonald | Chief Technology Officer | Senior Management | 2017 | 65 |
| Mark R. Sullivan | General Counsel; Secretary; Chief Compliance Officer | Senior Management | - | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward